DM / DNB Cardiology Entrance Mock Test 15
Source: Cardiophile MD - February 9, 2016 Category: Cardiology Authors: Prof. Dr. Johnson Francis, MD, DM, FACC, FRCP Edin, FRCP London Tags: Cardiology MCQ DM / DNB Cardiology Entrance Featured Source Type: blogs
The March of Legal Settlements Continues into 2015 - Daiichi Sankyo Settles Charges of Kickbacks to Doctors for $39 Million
We are just into January and have our first legal settlement by a major health care corporation of charges of giving physicians kickbacks to spur use of a commercial product. Like most such stories, this one got little notice. The most extensive report was in Ed Silverman's PharmaLot blog on the Wall Street Journal site.The Summary and Allegations The basic summary...Daiichi Sankyo agreed to pay $39 million to the U.S. federal government and state Medicaid programs to settle allegations of paying kickbacks to physicians to prescribe several of its drugs. The allegations were ...that Daiichi initiated different...
Source: Health Care Renewal - January 13, 2015 Category: Health Management Tags: conflicts of interest corporate integrity agreement Daiichi Sankyo impunity kickbacks legal settlements Source Type: blogs
Bile acid sequestrants
True statement/s regarding bile acid sequestrants: a) Inhibit the absorption of bile acids b) Depletion of cholesterol pool in the liver c) LDL receptor upregulation d) All of the above Correct answer: d) All of the above They occur sequentially. In addition they have a beneficial effect on glycemia, possibly mediated through incretins. Important drugs in this class are cholestyramine, colestipol and colesevelam. (Source: Cardiophile MD)
Source: Cardiophile MD - October 31, 2013 Category: Cardiology Authors: Prof. Dr. Johnson Francis MD, DM, FACC, FRCP Edin, FRCP London Tags: Cardiology MCQ DM / DNB Cardiology Entrance cholestyramine colesevelam colestipol incretins Source Type: blogs
The glass ceiling
Female sales reps: Daiichi Sankyo discriminates TRENTON, N.J. -- Six current and former female sales representatives are accusing drugmaker Daiichi Sankyo of gender discrimination in a $100 million class action lawsuit. The lawsuit states the women are trying to end employment discrimination for themselves and several hundred other female sales reps who currently work for or have worked for the U.S. arm of Daiichi Sankyo Co. Ltd. The Japanese pharmaceutical company makes cholesterol and blood pressure drugs. The suit alleges that the company pays female sales staff less than men for the same work, promotes women more sl...
Source: PharmaGossip - February 12, 2013 Category: Pharma Commentators Authors: insider Source Type: blogs